ONYX

Onyx Biotec Share Price

₹57.15 -2.35 (-3.95%)

07 Dec, 2024 14:27

SIP TrendupStart SIP in ONYX

Start SIP

Performance

  • Low
  • ₹57
  • High
  • ₹62
  • 52 Week Low
  • ₹51
  • 52 Week High
  • ₹63
  • Open Price₹60
  • Previous Close₹60
  • Volume198,000

Investment Returns

  • Over 1 Month -6.31%
  • Over 3 Month -6.31%
  • Over 6 Month -6.31%
  • Over 1 Year -6.31%
SIP Lightning

Smart Investing Starts Here Start SIP with Onyx Biotec for Steady Growth!

Invest Now

Onyx Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 104
  • P/B Ratio
  • 4.2
  • Average True Range
  • -
  • EPS
  • 1.67
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • -
  • MFI
  • -

Onyx Biotec Financials

Onyx Biotec Technicals

EMA & SMA

Current Price
₹57.15
-2.35 (-3.95%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 4
  • 20 Day
  • -
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

58.42 Pivot Speed
  • R3 65.13
  • R2 63.32
  • R1 60.23
  • S1 55.33
  • S2 53.52
  • S3 50.43

What's your outlook on Onyx Biotec?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

N/A

Group Rank

Onyx Biotec Limited specializes in manufacturing biopharmaceutical products across two key segments: vaccines and therapeutic proteins. Operating in over 30 countries, it has three advanced production facilities catering to healthcare providers and pharmaceutical companies globally for critical disease treatments.

Onyx Biotec Ltd has an operating revenue of Rs. 138.09 Cr. on a trailing 12-month basis. An annual revenue growth of 36% is outstanding, Pre-tax margin of 8% is okay, ROE of 12% is good. The company has a debt to equity of 95%, which is bit higher. The stock from a technical standpoint is trading close to its key moving averages, around 3% and 3% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 45 which is POOR indicating the underperformance as compared to other stocks, Group Rank of 54 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Onyx Biotec F&O

Onyx Biotec Shareholding Pattern

No data available.

About Onyx Biotec

  • NSE Symbol
  • ONYX
  • BSE Symbol
  • Managing Director
  • Mr. Sanjay Jain
  • ISIN
  • INE0WVU01018

Similar Stocks to Onyx Biotec

Onyx Biotec FAQs

Onyx Biotec share price is ₹57 As on 07 December, 2024 | 14:13

The Market Cap of Onyx Biotec is ₹103.6 Cr As on 07 December, 2024 | 14:13

The P/E ratio of Onyx Biotec is As on 07 December, 2024 | 14:13

The PB ratio of Onyx Biotec is 4.2 As on 07 December, 2024 | 14:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23